A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of Biobypass (ADGVVEGF121.10NH) delivered by NOGATM-guided/MYOSTARTM catheter in "no option" patients with class II-IV stable angina

×

Error message

  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (line 53 of /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (line 95 of /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of Biobypass (ADGVVEGF121.10NH) delivered by NOGATM-guided/MYOSTARTM catheter in "no option" patients with class II-IV stable angina
Date receipt dossier: 
5 Jul 2005
EudraCT number: 
2004-001250-91
Pharmaceutical study code: 
GV-002.001 (NOVA trial)
Company / Sponsor: 
GenVec, Inc.
Phase: 
II
Treated organism: 
Humans
Indication category: 
Cardiovascular therapy
Disease: 
Stable angina pectoris
Therapeutic approach: 
Gene therapy
Genetic modification: 
human VEGF121
Method of transfer of nucleic acid of interest: 
Human Adenovirus serotype 5
Administered biological material: 
Recombinant Adenovirus D (E1a and partially E1b and E3)
Route of administration: 
Intracardiac
Locations in Belgium: 
AZ Middelheim, Antwerpen
Type of procedure: 
Contained use only
Notes: 
study withdrawn by notifier